Valneva (NASDAQ:VALN) Sees Large Volume Increase – Should You Buy?

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) saw unusually-high trading volume on Monday . Approximately 42,338 shares traded hands during mid-day trading, an increase of 196% from the previous session’s volume of 14,284 shares.The stock last traded at $11.3670 and had previously closed at $10.98.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut shares of Valneva from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Valneva Price Performance

The company has a market cap of $982.48 million, a price-to-earnings ratio of -7.92 and a beta of 1.84. The company has a current ratio of 1.78, a quick ratio of 1.36 and a debt-to-equity ratio of 0.72. The company has a fifty day moving average price of $9.56 and a two-hundred day moving average price of $9.59.

Institutional Investors Weigh In On Valneva

Institutional investors and hedge funds have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. acquired a new stake in shares of Valneva during the 2nd quarter valued at about $8,240,000. JPMorgan Chase & Co. acquired a new position in Valneva in the third quarter worth about $124,000. XTX Topco Ltd acquired a new position in Valneva in the fourth quarter worth about $94,000. Marex Group plc bought a new position in Valneva during the second quarter worth about $64,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Valneva during the fourth quarter valued at approximately $44,000. Institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.